First Light Asset Management LLC Lowers Stake in Ultragenyx Pharmaceutical Inc. $RARE

First Light Asset Management LLC cut its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 47.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 285,699 shares of the biopharmaceutical company’s stock after selling 262,206 shares during the quarter. First Light Asset Management LLC’s holdings in Ultragenyx Pharmaceutical were worth $8,594,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in RARE. Norges Bank acquired a new position in Ultragenyx Pharmaceutical in the 2nd quarter valued at about $35,765,000. Hsbc Holdings PLC lifted its position in Ultragenyx Pharmaceutical by 88.6% during the 2nd quarter. Hsbc Holdings PLC now owns 97,197 shares of the biopharmaceutical company’s stock worth $3,554,000 after acquiring an additional 45,665 shares during the period. Skandinaviska Enskilda Banken AB publ grew its stake in shares of Ultragenyx Pharmaceutical by 108.1% in the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 67,720 shares of the biopharmaceutical company’s stock valued at $2,462,000 after purchasing an additional 35,185 shares during the last quarter. Frazier Life Sciences Management L.P. grew its stake in shares of Ultragenyx Pharmaceutical by 49.3% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 983,715 shares of the biopharmaceutical company’s stock valued at $35,768,000 after purchasing an additional 325,000 shares during the last quarter. Finally, Schroder Investment Management Group increased its holdings in shares of Ultragenyx Pharmaceutical by 27.2% in the second quarter. Schroder Investment Management Group now owns 336,173 shares of the biopharmaceutical company’s stock valued at $12,223,000 after purchasing an additional 71,888 shares during the period. 97.67% of the stock is owned by hedge funds and other institutional investors.

Key Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Phase‑3 win for DTX301 (OTC deficiency): Ultragenyx reported that its AAV8 gene therapy (DTX301) reduced ammonia ~18% versus placebo and maintained normal ammonia through 36 weeks in a late‑stage trial—an important efficacy readout that advances the program toward potential regulatory/commercial milestones. Read More.
• Neutral Sentiment: JPMorgan cuts price target but keeps an Overweight rating: JPMorgan lowered its target from $120 to $74 while maintaining an Overweight stance—reducing near‑term upside expectations but still signaling conviction in the company’s longer‑term potential relative to peers. Read More.
• Negative Sentiment: Multiple securities‑fraud class action notices and lead‑plaintiff deadlines: Several law firms and investor‑alert services (Schall, Robbins Geller, Faruqi, Rosen, Pomerantz, DJS, ClaimsFiler, etc.) have announced a securities class action covering purchases from Aug 3, 2023–Dec 26, 2025 and are soliciting lead‑plaintiff candidates (April 6, 2026 deadline). This increases legal and headline risk, can pressure the stock near term, and may create potential future liabilities. Read More.

Ultragenyx Pharmaceutical Stock Performance

RARE stock opened at $21.34 on Monday. The stock’s 50 day moving average price is $23.01 and its 200 day moving average price is $28.81. The firm has a market cap of $2.06 billion, a P/E ratio of -3.65 and a beta of 0.16. Ultragenyx Pharmaceutical Inc. has a 1 year low of $18.41 and a 1 year high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The company had revenue of $207.28 million for the quarter, compared to analysts’ expectations of $199.60 million. During the same period in the previous year, the business posted ($1.39) EPS. The business’s quarterly revenue was up 25.5% on a year-over-year basis. On average, research analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Wall Street Analyst Weigh In

RARE has been the subject of several analyst reports. HC Wainwright cut their price target on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. JPMorgan Chase & Co. dropped their price objective on shares of Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating on the stock in a research note on Thursday. Robert W. Baird cut their price objective on shares of Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating for the company in a research report on Tuesday, December 30th. Guggenheim reduced their target price on shares of Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating for the company in a research note on Monday, January 5th. Finally, Barclays lowered their target price on shares of Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating on the stock in a report on Monday, November 24th. Sixteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $65.76.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, EVP Karah Herdman Parschauer sold 8,135 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $185,478.00. Following the completion of the sale, the executive vice president owned 76,346 shares in the company, valued at approximately $1,740,688.80. This trade represents a 9.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Eric Crombez sold 7,029 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $160,261.20. Following the completion of the transaction, the executive vice president directly owned 76,301 shares of the company’s stock, valued at $1,739,662.80. The trade was a 8.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 104,958 shares of company stock valued at $2,394,858. 5.50% of the stock is owned by company insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.